CG Oncology, Inc. - Common stock (CGON)

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

One pundit believes this is a clinical-stage company well worth watching.

CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here's what to track...

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them?

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder cancer treatment at AUA 2025.

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

The companies are working on treatments for a form of bladder cancer.

As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.